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Abstract
The Icatibant Outcome Survey (IOS) is an observational study monitoring safety
and effectiveness of icatibant in the real-world setting. We analyzed safety data
from 3025 icatibant-treated attacks in 557 patients (enrolled between July 2009
and February 2015). Icatibant was generally well tolerated. Excluding off-label
use and pregnancy, 438 patients (78.6%) did not report adverse events (AEs).
The remaining 119 (21.4%) patients reported 341 AEs, primarily gastrointestinal
disorders (19.6%). Of these, 43 AEs in 17 patients (3.1%) were related to icati-
bant. Serious AEs (SAEs) occurred infrequently. A total of 143 SAEs occurred in
59 (10.6%) patients; only three events (drug inefficacy, gastritis, and reflux
esophagitis) in two patients were considered related to icatibant. Notably, no
SAEs related to icatibant occurred in patients with cardiovascular disease, nor in
those using icatibant at a frequency above label guidelines. Additionally, no
major differences were noted in AEs occurring in on-label vs off-label icatibant
users.
Icatibant has demonstrated tolerability and efficacy in
patients with hereditary angioedema with C1 inhibitor defi-
ciency (C1-INH-HAE) type I/II (1–5). Icatibant phase 3 stud-
ies included around 200 patients (228 attacks) and follow-up
periods ≤24 weeks (1, 2). No icatibant-related serious adverse
events (SAEs) were reported (1, 2). Nevertheless, considering
the limited number of patients enrolled and the short follow-
up, additional data are desirable.
Patient registries provide useful sources of additional data
on rare conditions. The Icatibant Outcome Survey (IOS;
NCT01034969) is an ongoing, international, prospective,
observational registry monitoring efficacy and safety of icati-
bant in the real-world setting. Preclinical studies have
suggested that icatibant-associated adverse events (AEs) may
relate to its mechanism of action (6, 7). The current analysis
evaluated incidence of cardiovascular-related AEs, as well as
other common AEs in icatibant-treated patients. The objec-
tive was to assess safety data from the IOS database.
Patients and methods
Eligible patients were currently receiving or were candidates
for icatibant use. Data were collected by physicians complet-
ing electronic forms with information from patients’ follow-
up visits; the protocol recommended every 6-month visits,
but visit frequency was not mandated. IOS is conducted per
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local ethics committees and/or health authorities at partici-
pating sites, the Declaration of Helsinki and the International
Conference on Harmonisation Good Clinical Practice guideli-
nes, and all patients provided written informed consent prior
to participation. Additional details regarding the IOS registry
have been previously described (8).
Safety data from the IOS reported herein were collected
between July 2009 and February 2015 from 47 participating
centers in 11 countries. Adverse events were categorized per
Medical Dictionary for Regulatory Activities (MedDRA)
system organ classification and analyzed by number/percent-
age of patients reporting a safety event and number/percent-
age of the occurrence of any safety event. The MedDRA
term ‘general disorders and administration site conditions’
encompassed the following: application site pain, chest dis-
comfort, chills, drug ineffective, drug intolerance, edema,
fatigue, feeling hot, gait disturbance, hyperhidrosis, hyper-
plasia, influenza-like illness, infusion site pain, injection site
erythema, injection site pain, injection site urticaria, localized
edema, local swelling, malaise, noncardiac chest pain, pain,
peripheral edema, pyrexia, and therapeutic product ineffec-
tive. Although pregnancy and off-label use (defined as
patients with angioedema other than HAE type I/II or
occurrence of AEs in patients <18 years) were documented
as AEs in the IOS registry from a regulatory standpoint,
these events were not considered clinically meaningful AEs
and therefore were analyzed separately from our safety
analysis.
Results
Patients
As of February 2015, ≥1 dose of icatibant was used to treat
3025 attacks in 557 patients. Mean age [standard deviation
(SD)] at enrollment was 41.6 (15.2) years, with a female/male
gender distribution of 63.6/36.4%.
Of patients with documented ethnicity (n = 540), most
were white (93.3%). A total of 378 (69.9%) and 23 (4.3%)
patients had C1-INH-HAE type I/II, respectively; the
remaining patients (n = 140, 25.9%) had HAE with normal
C1-INH, angiotensin converting enzyme (ACE) inhibitor-
induced angioedema, idiopathic angioedema, acquired
angioedema (CI-INH-AAE), or other (missing diagnoses,
n = 16). Demographic parameters varied across HAE types.
For instance, mean (SD) age at diagnosis was lower for
patients with C1-INH-HAE type I/II [24.0 (16.0) years] and
HAE with normal C1-INH [36.0 (14.3) years] vs those with
idiopathic angioedema [44.7 (13.7) years], CI-INH-AAE [59.2
(9.7) years], and ACE inhibitor-induced angioedema [73.2
(6.1) years]. However, patients with CI-INH-AAE and ACE
inhibitor-induced angioedema had a shorter mean (SD) delay
between symptom onset and diagnosis [1.0 (1.2) and 1.7
(2.6) years, respectively] vs those with idiopathic angioedema
[8.4 (10.8) years], C1-INH-HAE type I/II [10.1 (13.5) years],
or HAE with normal C1-INH [11.1 (11.3) years].
Since entry into the IOS, the overall patient population
was followed for a mean (SD) of 2.97 (1.42) years (<1 year,
10.2%; 1–2 years, 19.4%; 2–3 years, 17.2%; 3–4 years,
24.1%; 4–5 years, 26%, and ≥5 years, 3.1%). Follow-up
times were similar across HAE subtypes. In total, patients
were followed for 1655.2 icatibant-treated patient years.
AEs overall
Most icatibant-treated patients (n = 438, 78.6%) did not
report an AE; the remaining 119 (21.4%) reported 341 AEs.
The most commonly reported events were gastrointestinal (GI)
disorders (19.6%), general disorders and administration site
conditions (13.8%), infections and infestations (11.1%), respi-
ratory, thoracic, and mediastinal disorders (8.8%), muscu-
loskeletal and connective tissue disorders (6.5%), and skin and
subcutaneous tissue disorders (6.5%). All other AEs repre-
sented <5% of total events. No major differences were noted in
AEs occurring in on-label vs off-label icatibant users.
AEs related to icatibant
A total of 17 patients (3.1%) reported 43 treatment-related
events (Table 1). Of these, 19 events (44.2%) in five patients
were considered possibly related, and 24 events (55.8%) in 12
patients probably related. The most common treatment-
related AEs were general disorders and administration site
conditions (53.5%), GI disorders (11.6%), investigations
(weight or blood pressure decreases, 11.6%), vascular disor-
ders (hyperemia, 9.3%), and nervous system disorders
(7.0%).
Serious adverse events
A total of 59 patients (10.6%) reported 143 SAEs (Table 2).
The most common events were GI disorders (28%), respira-
tory, thoracic, and mediastinal disorders (12.6%), neoplasms
(benign, malignant, or unspecified, 8.4%), general disorders
and administration site conditions (7.7%), and infections and
infestations (7.7%). Three SAEs (drug inefficacy, gastritis,
reflux oesophagitis) in two patients were considered possibly
or probably related to icatibant.
AEs in patients with cardiovascular disease
Cardiovascular disease (CVD) was reported in 95 icatibant-
treated patients. At time of enrollment, patients reported:
hypertension (n = 80), transient ischemic attack (TIA) or
stroke (n = 5), angina (n = 4), and ischemic heart disease
(n = 3). At follow-up, the following new onset CVDs were
reported: hypertension (n = 5), angina (n = 1), ischemic heart
disease (n = 1), and TIA or stroke (n = 1). Additionally at
follow-up, hypertension was reported in three patients whose
CVD history was missing at baseline.
A total of 22 (23.2%) patients with CVD reported 49 AEs,
most commonly general disorders and administration site
conditions (eight events, 16.3%), respiratory, thoracic, and
mediastinal disorders (seven events, 14.3%), and GI disorders
(five events, 10.2%). Of AEs occurring in patients with CVD,
13 events in three patients were considered possibly or
Allergy 72 (2017) 994–998 © 2016 The Authors. Allergy Published by John Wiley & Sons Ltd. 995
Zanichelli et al. Real-world long-term safety of icatibant
probably related to icatibant, with the majority being general
disorders and administration site conditions (eight events,
61.5%). Sixteen patients reported 24 SAEs, none of which
were considered related to icatibant.
AEs in patients who used icatibant at a frequency above label
guidelines
Per the icatibant summary of product characteristics, ≤8 icat-
ibant injections per month have been administered in clinical
trials (9). In the IOS registry, of 10 patients who received ≥9
icatibant injections in 1 month, drug ineffectiveness was
reported in two patients. The icatibant package information
recommends an interval of ≥6 h between doses and no more
than three doses in 24 h (10). In the IOS registry, no AEs
were reported by 13 patients whose intervals between icati-
bant doses were <6 h, nor in four patients who received icati-
bant more frequently than three times in 24 h.
Discussion
Overall, no unexpected safety signals emerged in this large
database, and AEs were similar in off-label vs on-label users.
General disorders and administration site conditions occurred
in 13.8% of icatibant-treated patients, including but not lim-
ited to local injection site reactions. Occurrence of these reac-
tions was notably lower than their 97% incidence in icatibant
clinical trials (10), especially since the 13.8% incidence may
be an overestimation (given that these reactions were
recorded as part of a larger bucket of events). This discrep-
ancy may reflect multiple factors, including differences in the
processes followed for reporting and documenting such reac-
tions in a real-world setting vs a controlled environment.
Whereas in a clinical trial setting investigators proactively
document occurrence of all (including very minor and tran-
sient) injection site reactions in a detailed manner upon their
immediate occurrence, in a drug registry setting, such reac-
tions are documented retrospectively, possibly leading to
recall bias. Patients may fail to report a well-tolerated local
reaction, or the investigators may choose not to document
this expected, minor reaction as an AE. The extended time
lapse between occurrences of angioedema attacks and when
patients report AEs during follow-up visits may further
Table 1 AEs (excluding off-label use* and pregnancy) considered
by the investigator to be possibly or probably related to icatibant
Icatibant-treated patients (n = 557)
Number of
events related
to icatibant
use (%)
Number of
patients
experiencing
icatibant-related
events (%)
Any event 43 (100.0) 17 (3.1)
Drug ineffective 6 (14.0) 5 (0.9)
Injection site erythema 6 (14.0) 1 (0.2)
Blood pressure decreased 4 (9.3) 1 (0.2)
Hyperemia 4 (9.3) 3 (0.5)
Pain 3 (7.0) 2 (0.4)
Gastritis 2 (4.7) 1 (0.2)
Application site pain 1 (2.3) 1 (0.2)
Chest discomfort 1 (2.3) 1 (0.2)
Cholelithiasis 1 (2.3) 1 (0.2)
Depression 1 (2.3) 1 (0.2)
Dizziness 1 (2.3) 1 (0.2)
Epigastric discomfort 1 (2.3) 1 (0.2)
Feeling hot 1 (2.3) 1 (0.2)
Headache 1 (2.3) 1 (0.2)
Herpes zoster 1 (2.3) 1 (0.2)
Infusion site pain 1 (2.3) 1 (0.2)
Injection site pain 1 (2.3) 1 (0.2)
Injection site urticaria 1 (2.3) 1 (0.2)
Nausea 1 (2.3) 1 (0.2)
Noncardiac chest pain 1 (2.3) 1 (0.2)
Therapeutic
product ineffective
1 (2.3) 1 (0.2)
Postherpetic neuralgia 1 (2.3) 1 (0.2)
Reflux oesophagitis 1 (2.3) 1 (0.2)
Weight decreased 1 (2.3) 1 (0.2)
AEs, adverse events.
*Off-label use refers to patients with angioedema other than HAE
type I or II or those in whom AEs occurred prior to 18 years of
age.
Table 2 SAEs (excluding off-label* use and pregnancy) occurring
with a frequency of >1% of total events
Icatibant-treated patients
(n = 557)
Number of
events (%)
Number of
patients (%)
Any event 143 (100.0) 59 (10.6)
Abdominal pain 8 (5.6) 7 (1.3)
Angioedema 4 (2.8) 4 (0.7)
Diarrhea 4 (2.8) 2 (0.4)
Peripheral edema 4 (2.8) 2 (0.4)
Abdominal distension 3 (2.1) 3 (0.5)
Face swelling 3 (2.1) 3 (0.5)
Laryngeal edema 3 (2.1) 3 (0.5)
Abdominal hernia 2 (1.4) 2 (0.4)
Abdominal pain (upper) 2 (1.4) 2 (0.4)
Colonic polyp 2 (1.4) 1 (0.2)
Cough 2 (1.4) 2 (0.4)
Dyspnoea 2 (1.4) 2 (0.4)
Hematochezia 2 (1.4) 1 (0.2)
Hereditary angioedema 2 (1.4) 2 (0.4)
Legionella infection 2 (1.4) 1 (0.2)
Local administration site swelling 2 (1.4) 2 (0.4)
Myelodysplastic syndrome 2 (1.4) 1 (0.2)
Pyrexia 2 (1.4) 2 (0.4)
Respiratory failure 2 (1.4) 1 (0.2)
Suicide attempt 2 (1.4) 2 (0.4)
SAEs, serious adverse events.
*Off-label use refers to patients with angioedema other than HAE
type I or II or those in whom adverse events occurred prior to
18 years of age.
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contribute to underreporting. Nonetheless, our findings pre-
sent a real-world perspective with regard to icatibant tolera-
bility, which may indeed differ somewhat from findings in
clinical trials.
Serious adverse events occurred infrequently, and none
were cardiovascular-related. Studies have shown that brady-
kinin B2 receptor blockade might impair endothelial repair
after an acute cardiovascular event (6, 7). However, icatibant
has a short half-life (9) and the effect of intermittent treat-
ments is likely transient.
Potential limitations of the IOS study were the uncon-
trolled clinical environment inherent in an observational
study design, as well as possible inconsistences in patient
and physician-based reporting of AEs across registry study
sites. Nonetheless, observational registries offer valuable
insights into the safety and efficacy of treatments in real-
world settings.
Our results show that icatibant was generally well toler-
ated; incidence and severity of AEs was not greater than was
expected in this patient population. No major differences
were noted in on-label vs off-label icatibant users, and no
SAEs occurred in patients with CVD using icatibant.
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